This week PharmaShots’ news was all about the updates on  regulatory, M&A   pharma, and Clinical Trials . Check out our full report below:

AstraZeneca’s Imfinzi + CT Received NMPA Approval for the treatment of Locally Advanced/metastatic Biliary Tract Cancer  

Read More: AstraZeneca                                                                     

Roche received the EU’s CHMP Positive Opinion for the approval of subcutaneous injection of Tecentriq 

Read More: Roche                                                                               

BMS Receives the US FDA’s Approval for Augtyro (repotrectinib) to Treat Non-Small Cell Lung Cancer (NSCLC)

Read More: BMS                                                                                     

The European Commission Approved argenx’s Vyvgart with Halozyme’s Enhanze for the Treatment of Generalized Myasthenia Gravis

Read More: argenx & Halozyme                                                           

Praxis Precision's elsunersen has been awarded the PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)

 Read More: Praxis Precision                                                             

Ajinomoto to acquire Forge Biologics for $620M

Read More: Ajinomoto & Forge Biologics                                         

For ~$175 million, Astellas acquires Propella Therapeutics

Read More: Astellas & Propella Therapeutics                                    

The US FDA Approved Cormedix’s DefenCath for the Reduction of Catheter-Related Bloodstream Infections (CRBSI) In Adult Hemodialysis Patients

Read More: Cormedix                                                                               

For ~$180 million, GTCR to Acquire Cloudbreak Health

Read More: GTCR                                                                                     

Q32 Bio Re-Acquires the Rights to Bempikibart (ADX-914) for Autoimmune Diseases from Amgen

Read More: Q32 Bio                                                                             

Intercept Pharmaceutical highlights the P-II trial  results for OCA + Bezafibrate to treat PBC-Induced Liver Damage

Read More: Intercept Pharmaceutical                                                

Kite (Gilead) Expands its Collaboration Agreement with Arcellx for CART-DdBCMA to Treat Multiple Myeloma

Read More: Kite & Arcellx                                                                     

New data presented at AHA 2023 for zodasiran  by Arrowhead

Read More: Arrowhead                                                                           

New data presented at AHA 2023 for plozasiran  by Arrowhead 

Read More: Arrowhead                                                                

Vertex and CRISPR Therapeutics Received Conditional Marketing Authorization for Casgevy by the United Kingdom MHRA to Treat Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Read More: Vertex & CRISPR Therapeutics                               

Tonix Pharmaceuticals Highlights the P-III Trial Results of TNX-102 SL for the Management of Fibromyalgia 

Read More: Tonix Pharmaceuticals                                             

SpringWorks Therapeutics Highlights the P-IIb Trial Results for Mirdametinib to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)

Read More: SpringWorks Therapeutics                                       

AbbVie Publishes the P-III Trial Results for Ubrelvy (ubrogepant) as Treatment for Migraine in ‘The Lancet’

Read More: AbbVie                          

Related Post:- PharmaShots Weekly Snapshots (November 06–10, 2023)